Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine effica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624448/
https://ncbi.nlm.nih.gov/pubmed/24687088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-540971
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars